GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a ...

The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of ...

The GSK share price is nearly 10% off its 52-week high, and this Fool is keen to take a closer look. Could it be a stock for ...

GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...

Therefore, a fair value for the shares would be ... Zantac was first linked to cancer in 2019. GSK had previously settled various lawsuits. However, on 31 May a US court in Delaware ruled that 70,000+ ...

IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

This content summarizes significant health news, including the impact of the Affordable Care Act, new weight-loss drugs, the ...

Bronchoscopic lung volume reduction (BLVR) was associated with sustained improvements in adults with severe emphysema over a 5-year period, based on data from 190 individuals. The LIBERATE study, a ...

PRESS RELEASECHARM Therapeutics appoints Dr Beverley Carr as Chief Business OfficerHighly experienced dealmaker to lead CHARM ...